Low-intervention clinical trials in Spain : Do they progress?
Delgado Espinoza, Claudia Erika (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Cortes Pestana, Mayro Jaime (Institut de Recerca Sant Pau)
Antonijoan Arbós, Rosa Ma (Rosa María) (Institut de Recerca Sant Pau)
Pontes García, Caridad (Institut de Recerca Sant Pau)
Amaro-Hosey, Kristopher (Institut de Recerca Sant Pau)
Pontes García, Caridad (Institut de Recerca Sant Pau)

Publicación:	Wiley-Blackwell Publishing Ltd, 2025
Descripción:	7 pàg.
Resumen:	AIMS: Low-Intervention Clinical Trials (LICTs) are generally pragmatic trials that investigate medicinal products already authorized for use. In 2014, simplified regulatory frameworks were introduced for LICTs with the aim of reducing regulatory burden and operational complexity, to foster non-commercial clinical trials (NCCTs); the mandatory implementation of CTIS in 2023 may have impacted LICTs feasibility. Our aim was to describe the main characteristics of LICTs approved in Spain over a ten-year period. METHODS: Cross-sectional descriptive analysis of LICTs registered between 2014 and 2023, in the Spanish Clinical Studies Registry (REec) database, mandatory to all authorized trials. RESULTS: Between January 2014 and December 2023, 8497 clinical trials were registered in REec, of which only 3. 8% (N = 322) were classified as LICTs. No drop in the overall proportion of LICTs was seen in 2023. Most LICTs were sponsored by non-commercial entities and funded primarily through sponsors' own resources. LICTs were frequently monocentric phase IV studies evaluating commercialized medicinal products. The principal objectives of the trials included efficacy and/or safety, while pharmacoeconomics, pharmacogenetics, pharmacogenomics and bioequivalence were comparatively infrequent as main objectives. Most trial designs were randomized, but blinded trials were less frequent, and only a minority were placebo-controlled. CONCLUSIONS: Despite their critical role in establishing effectiveness and safety of authorized medicinal products in pragmatic clinical settings, LICTs still constitute a relatively small proportion of all clinical trials approved in Spain, and their designs have area for improvement in terms of robustness. There was no apparent effect of CTIS implementation on LICTs activity.
Nota:	Altres ajuts: acords transformatius de la UAB
Derechos:	Aquesta url de drets no existeix a la base de dades.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió definida a EGRETA: publishersversion
Materia:	Clinical trials ; Low-intervention clinical trials ; Non-commercial clinical research ; Regulation
Publicado en:	British Journal of Clinical Pharmacology, ISSN 1365-2125

Adreça original del document, elimineu-la del registre: https://egreta.uab.cat/ws/files/520426939/Br_J_Clin_Pharmacol_-_2025_-_Delgado_Espinoza_-_Low_intervention_clinical_trials_in_Spain_Do_they_progress.pdf
DOI: 10.1002/bcp.70409
PMID: 41406957

7 p, 747.4 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados